180 related articles for article (PubMed ID: 34452244)
1. Structure-Activity Relationships of Benzothiazole-Based Hsp90 C-Terminal-Domain Inhibitors.
Dernovšek J; Zajec Ž; Durcik M; Mašič LP; Gobec M; Zidar N; Tomašič T
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452244
[TBL] [Abstract][Full Text] [Related]
2. From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition.
Pugh KW; Zhang Z; Wang J; Xu X; Munthali V; Zuo A; Blagg BSJ
ACS Med Chem Lett; 2020 Aug; 11(8):1535-1538. PubMed ID: 32832020
[TBL] [Abstract][Full Text] [Related]
3. In Silico Discovery and Optimisation of a Novel Structural Class of Hsp90 C-Terminal Domain Inhibitors.
Zajec Ž; Dernovšek J; Gobec M; Tomašič T
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883440
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.
Garg G; Zhao H; Blagg BS
ACS Med Chem Lett; 2015 Feb; 6(2):204-9. PubMed ID: 25699150
[TBL] [Abstract][Full Text] [Related]
8. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
10. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding.
Mak OW; Sharma N; Reynisson J; Leung IKH
Bioorg Med Chem Lett; 2021 Apr; 38():127857. PubMed ID: 33609661
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
13. Synthetic approaches, anticancer potential, HSP90 inhibition, multitarget evaluation, molecular modeling and apoptosis mechanistic study of thioquinazolinone skeleton: Promising antibreast cancer agent.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Chem; 2020 Aug; 101():103987. PubMed ID: 32540783
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32.
Chatterjee BK; Jayaraj A; Kumar V; Blagg B; Davis RE; Jayaram B; Deep S; Chaudhuri TK
J Biol Chem; 2019 Apr; 294(16):6450-6467. PubMed ID: 30792306
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors.
Mettu A; Talla V; Bajaj DM; Subhashini NJP
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900063. PubMed ID: 31411362
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N-terminal Inhibitors Without Induction of Heat Shock Response.
Liu P; Chen X; Zhu J; Li B; Chen Z; Wang G; Sun H; Xu Z; Zhao Z; Zhou C; Xie C; Lou L; Zhu W
ChemistryOpen; 2019 Mar; 8(3):344-353. PubMed ID: 30976475
[TBL] [Abstract][Full Text] [Related]
17. Novobiocin Analogs as Potential Anticancer Agents.
Dlugosz A; Janecka A
Mini Rev Med Chem; 2017; 17(9):728-733. PubMed ID: 28019639
[TBL] [Abstract][Full Text] [Related]
18. Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-
Liu Y; Li C; Li Y; Zhang S; Zhang N; Bian X; Tan S
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290912. PubMed ID: 38083866
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
20. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
Rampogu S; Parate S; Parameswaran S; Park C; Baek A; Son M; Park Y; Park SJ; Lee KW
Comput Biol Chem; 2019 Dec; 83():107113. PubMed ID: 31493740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
